Glaukos Corp (GKOS)

$170.99 +0.06 (0.04%)
Market Cap 10.08B
Revenue (ttm) 507.44M
Net Income (ttm) -187.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -36.99%
Debt to Equity Ratio 0.00
Volume 574,900
Avg Vol 1,004,528
Day's Range N/A - N/A
Shares Out 58.98M
Stochastic %K 66%
Beta 0.78
Analysts Strong Sell
Price Target $188.33

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
OpenOutcrier
OpenOutcrier Jul. 30 at 12:06 PM
$GKOS (+8.7% pre) Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates https://ooc.bz/l/109212
0 · Reply
biotech_loser
biotech_loser Jul. 30 at 12:05 PM
$GKOS the multiple is outrageous
0 · Reply
STACKD0E
STACKD0E Jul. 30 at 2:29 AM
$SMTI $GKOS ✨
0 · Reply
EarningsInsider
EarningsInsider Jul. 29 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-7-29-glaukos-co-stock/ $GKOS Glaukos Earnings Transcript
0 · Reply
topstockalerts
topstockalerts Jul. 29 at 9:37 PM
$GKOS this chart is slowly winning people over.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 29 at 9:08 PM
$GKOS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.31 up 8.82% YoY • Reported revenue of $185.61M up 49.54% YoY
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 8:33 PM
$GKOS Glaukos raises FY26 revenue view to $680M-$700M, consensus $629.98M Previous view $620M-$635M.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 8:33 PM
$GKOS Glaukos reports Q2 adjusted EPS (14c), consensus (21c) Reports Q2 revenue $185.6M, consensus $150.91M. "Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 8:06 PM
$ALVO $GKOS $OTLK $GDYN flipped the tape and closed with force. accumulation, short covering, or one last squeeze? the close holds the clue
0 · Reply
Profitrip
Profitrip Jul. 29 at 7:06 PM
$META $MSFT $GKOS $MORN $ALGN on my earnings high IV scan / reports ah!
1 · Reply
Latest News on GKOS
Glaukos Slides: Investor presentation

Jul 31, 2026, 7:00 AM EDT - 7 days ago

Glaukos Slides: Investor presentation

Glaukos price target raised to $195 from $168 at H.C. Wainwright

2026-07-30T16:50:21.000Z - 7 days ago

Glaukos price target raised to $195 from $168 at H.C. Wainwright

Glaukos price target raised to $172 from $150 at UBS

2026-07-30T13:22:15.000Z - 8 days ago

Glaukos price target raised to $172 from $150 at UBS

Glaukos price target raised to $193 from $164 at BTIG

2026-07-30T11:46:38.000Z - 8 days ago

Glaukos price target raised to $193 from $164 at BTIG

Glaukos price target raised to $201 from $150 at Needham

2026-07-30T11:42:41.000Z - 8 days ago

Glaukos price target raised to $201 from $150 at Needham

Glaukos price target raised to $190 from $175 at Stifel

2026-07-30T11:27:50.000Z - 8 days ago

Glaukos price target raised to $190 from $175 at Stifel

Glaukos price target raised to $195 from $165 at Piper Sandler

2026-07-30T11:01:28.000Z - 8 days ago

Glaukos price target raised to $195 from $165 at Piper Sandler

Glaukos price target raised to $188 from $175 at Citi

2026-07-30T11:01:09.000Z - 8 days ago

Glaukos price target raised to $188 from $175 at Citi

Glaukos price target raised to $178 from $138 at Wells Fargo

2026-07-30T10:30:57.000Z - 8 days ago

Glaukos price target raised to $178 from $138 at Wells Fargo

Glaukos Earnings Call Transcript: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Glaukos Earnings Call Transcript: Q2 2026

Glaukos Earnings release: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Glaukos Earnings release: Q2 2026

Glaukos Quarterly report: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 8 days ago

Glaukos Quarterly report: Q2 2026

Glaukos raises FY26 revenue view to $680M-$700M, consensus $629.98M

2026-07-29T20:22:42.000Z - 8 days ago

Glaukos raises FY26 revenue view to $680M-$700M, consensus $629.98M

Glaukos reports Q2 adjusted EPS (14c), consensus (21c)

2026-07-29T20:15:35.000Z - 8 days ago

Glaukos reports Q2 adjusted EPS (14c), consensus (21c)

Glaukos Announces Second Quarter 2026 Financial Results

Jul 29, 2026, 4:05 PM EDT - 8 days ago

Glaukos Announces Second Quarter 2026 Financial Results

Glaukos assumed with Neutral from Buy at UBS

2026-07-28T10:47:10.000Z - 10 days ago

Glaukos assumed with Neutral from Buy at UBS

Glaukos completes patient enrollment in 510k study for PRESERFLO

2026-07-27T11:10:20.000Z - 11 days ago

Glaukos completes patient enrollment in 510k study for PRESERFLO

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Jul 27, 2026, 7:00 AM EDT - 11 days ago

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Glaukos price target raised to $175 from $170 at Stifel

2026-07-17T12:21:01.000Z - 21 days ago

Glaukos price target raised to $175 from $170 at Stifel

Glaukos price target raised to $180 from $160 at Truist

2026-07-16T14:05:29.000Z - 22 days ago

Glaukos price target raised to $180 from $160 at Truist

Glaukos price target raised to $164 from $162 at BTIG

2026-07-13T11:20:30.000Z - 25 days ago

Glaukos price target raised to $164 from $162 at BTIG

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Jul 8, 2026, 7:00 AM EDT - 4 weeks ago

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Glaukos price target raised to $175 from $162 at Citi

2026-07-08T10:41:20.000Z - 4 weeks ago

Glaukos price target raised to $175 from $162 at Citi

Glaukos initiated with a Buy at H.C. Wainwright

2026-07-06T10:05:08.000Z - 4 weeks ago

Glaukos initiated with a Buy at H.C. Wainwright

Glaukos completes patient enrollment in Phase 2 study of GLK-321

2026-06-25T11:06:03.000Z - 6 weeks ago

Glaukos completes patient enrollment in Phase 2 study of GLK-321

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Jun 25, 2026, 7:00 AM EDT - 6 weeks ago

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Glaukos Transcript: Truist Securities MedTech Conference 2026

Jun 16, 2026, 9:20 AM EDT - 7 weeks ago

Glaukos Transcript: Truist Securities MedTech Conference 2026

Glaukos Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:10 AM EDT - 2 months ago

Glaukos Transcript: Jefferies Global Healthcare Conference 2026

Glaukos Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 1:00 PM EDT - 2 months ago

Glaukos Transcript: 46th Annual William Blair Growth Stock Conference

Glaukos Transcript: AGM 2026

May 28, 2026, 12:00 PM EDT - 2 months ago

Glaukos Transcript: AGM 2026

Glaukos Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 1:30 PM EDT - 2 months ago

Glaukos Transcript: Stifel 2026 Virtual Ophthalmology Forum

Glaukos Announces Participation in Upcoming Investor Conferences

May 12, 2026, 7:00 AM EDT - 3 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Slides: Investor presentation

May 1, 2026, 7:00 AM EDT - 3 months ago

Glaukos Slides: Investor presentation

Glaukos Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Glaukos Earnings Call Transcript: Q1 2026

Glaukos Earnings release: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Glaukos Earnings release: Q1 2026

Glaukos Quarterly report: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Glaukos Quarterly report: Q1 2026

Glaukos Announces First Quarter 2026 Financial Results

Apr 29, 2026, 4:05 PM EDT - 3 months ago

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Glaukos Proxy statement: Proxy filing

Glaukos Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Glaukos Proxy statement: Proxy filing

Glaukos Announces the Release of its 2025 Sustainability Report

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Apr 15, 2026, 4:05 PM EDT - 4 months ago

Glaukos Receives Permanent J-code for Epioxa™

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Slides: Investor presentation

Mar 5, 2026, 7:00 AM EST - 5 months ago

Glaukos Slides: Investor presentation

Glaukos Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Glaukos Earnings Call Transcript: Q4 2025

Glaukos Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Glaukos Annual report: Q4 2025

Glaukos Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 6 months ago

Glaukos Earnings release: Q4 2025

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 17, 2026, 4:05 PM EST - 6 months ago

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Jan 28, 2026, 7:00 AM EST - 6 months ago

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Jan 20, 2026, 7:00 AM EST - 7 months ago

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Glaukos Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 7 months ago

Glaukos Transcript: 44th Annual J.P. Morgan Healthcare Conference

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Jan 13, 2026, 4:05 PM EST - 7 months ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Slides: Investor presentation

Jan 12, 2026, 4:00 PM EST - 7 months ago

Glaukos Slides: Investor presentation

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 16, 2025, 7:00 AM EST - 8 months ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 1:45 PM EST - 8 months ago

Glaukos Transcript: Citi Annual Global Healthcare Conference 2025

Glaukos Transcript: Stephens Annual Investment Conference

Nov 18, 2025, 11:00 AM EST - 9 months ago

Glaukos Transcript: Stephens Annual Investment Conference

Glaukos Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 1:20 PM EST - 9 months ago

Glaukos Transcript: Stifel 2025 Healthcare Conference

Glaukos Transcript: UBS Global Healthcare Conference 2025

Nov 11, 2025, 10:15 AM EST - 9 months ago

Glaukos Transcript: UBS Global Healthcare Conference 2025

Glaukos Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 9 months ago

Glaukos Slides: Corporate Presentation

Glaukos Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Glaukos Earnings Call Transcript: Q3 2025

Glaukos Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Glaukos Quarterly report: Q3 2025

Glaukos Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Glaukos Earnings release: Q3 2025

Glaukos Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 10 months ago

Glaukos Announces Third Quarter 2025 Financial Results

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:10 AM EDT - 10 months ago

US FDA approves Glaukos' new eye therapy

Glaukos Announces FDA Approval of Epioxa™

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Glaukos Announces FDA Approval of Epioxa™

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 14, 2025, 7:00 AM EDT - 10 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Oct 8, 2025, 7:00 AM EDT - 10 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Sep 25, 2025, 4:05 PM EDT - 11 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Glaukos Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 10:15 AM EDT - 1 year ago

Glaukos Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Earnings Call Transcript: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings Call Transcript: Q2 2025

Glaukos Quarterly report: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Quarterly report: Q2 2025

Glaukos Earnings release: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings release: Q2 2025

Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2025 Financial Results

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 4:05 PM EDT - 1 year ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Glaukos Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:45 AM EDT - 1 year ago

Glaukos Transcript: Jefferies Global Healthcare Conference 2025

Glaukos Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 1:40 PM EDT - 1 year ago

Glaukos Transcript: 45th Annual William Blair Growth Stock Conference

Glaukos Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 12:30 PM EDT - 1 year ago

Glaukos Transcript: Stifel 2025 Virtual Ophthalmology Forum

Glaukos Slides: Investor Presentation

May 14, 2025, 7:00 AM EDT - 1 year ago

Glaukos Slides: Investor Presentation

Glaukos Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings Call Transcript: Q1 2025

Glaukos Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Quarterly report: Q1 2025

Glaukos Earnings release: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings release: Q1 2025

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2025 Financial Results

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Glaukos Proxy statement: Proxy Filing

Glaukos Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Glaukos Proxy statement: Proxy Filing

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 1 year ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Earnings Call Transcript: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Earnings Call Transcript: Q4 2024

Glaukos Annual report: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Annual report: Q4 2024

Glaukos Earnings release: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Earnings release: Q4 2024

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 8:15 PM EST - 1 year ago

Glaukos Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Glaukos Slides: FY 2025

Jan 14, 2025, 8:15 PM EST - 1 year ago

Glaukos Slides: FY 2025

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos Slides: Investor Presentation

Jan 14, 2025, 7:00 AM EST - 1 year ago

Glaukos Slides: Investor Presentation

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Transcript: Citi's 2024 Global Healthcare Conference

Dec 5, 2024, 9:30 AM EST - 1 year ago

Glaukos Transcript: Citi's 2024 Global Healthcare Conference

Glaukos Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 1:00 PM EST - 1 year ago

Glaukos Transcript: Piper Sandler 36th Annual Healthcare Conference

Glaukos Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 20, 2024, 10:00 AM EST - 1 year ago

Glaukos Transcript: Stephens 26th Annual Investment Conference | NASH2024

Glaukos Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 12:40 PM EST - 1 year ago

Glaukos Transcript: Stifel 2024 Healthcare Conference

Glaukos Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Earnings Call Transcript: Q3 2024

Glaukos Quarterly report: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Quarterly report: Q3 2024

Glaukos Earnings release: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Earnings release: Q3 2024

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 2 years ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 12:20 PM EDT - 2 years ago

Glaukos Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Glaukos Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 12:45 PM EDT - 2 years ago

Glaukos Transcript: 2024 Wells Fargo Healthcare Conference

Glaukos Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings Call Transcript: Q2 2024

Glaukos Quarterly report: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Quarterly report: Q2 2024

Glaukos Earnings release: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings release: Q2 2024

Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces Second Quarter 2024 Financial Results

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jul 10, 2024, 7:00 AM EDT - 2 years ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Transcript: 2024 Truist Securities MedTech Conference

Jun 18, 2024, 12:45 PM EDT - 2 years ago

Glaukos Transcript: 2024 Truist Securities MedTech Conference

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 14, 2024, 7:00 AM EDT - 2 years ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos Transcript: The 44th Annual William Blair Growth Stock Conference

Jun 5, 2024, 1:40 PM EDT - 2 years ago

Glaukos Transcript: The 44th Annual William Blair Growth Stock Conference

Glaukos Transcript: AGM 2024

May 30, 2024, 12:00 PM EDT - 2 years ago

Glaukos Transcript: AGM 2024

Glaukos Earnings Call Transcript: Q1 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings Call Transcript: Q1 2024

Glaukos Quarterly report: Q1 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Quarterly report: Q1 2024

Glaukos Earnings release: Q1 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings release: Q1 2024

Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 16, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Glaukos Proxy statement: Proxy Filing

Glaukos Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Glaukos Proxy statement: Proxy Filing

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

OpenOutcrier
OpenOutcrier Jul. 30 at 12:06 PM
$GKOS (+8.7% pre) Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates https://ooc.bz/l/109212
0 · Reply
biotech_loser
biotech_loser Jul. 30 at 12:05 PM
$GKOS the multiple is outrageous
0 · Reply
STACKD0E
STACKD0E Jul. 30 at 2:29 AM
$SMTI $GKOS ✨
0 · Reply
EarningsInsider
EarningsInsider Jul. 29 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-7-29-glaukos-co-stock/ $GKOS Glaukos Earnings Transcript
0 · Reply
topstockalerts
topstockalerts Jul. 29 at 9:37 PM
$GKOS this chart is slowly winning people over.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 29 at 9:08 PM
$GKOS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.31 up 8.82% YoY • Reported revenue of $185.61M up 49.54% YoY
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 8:33 PM
$GKOS Glaukos raises FY26 revenue view to $680M-$700M, consensus $629.98M Previous view $620M-$635M.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 8:33 PM
$GKOS Glaukos reports Q2 adjusted EPS (14c), consensus (21c) Reports Q2 revenue $185.6M, consensus $150.91M. "Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 8:06 PM
$ALVO $GKOS $OTLK $GDYN flipped the tape and closed with force. accumulation, short covering, or one last squeeze? the close holds the clue
0 · Reply
Profitrip
Profitrip Jul. 29 at 7:06 PM
$META $MSFT $GKOS $MORN $ALGN on my earnings high IV scan / reports ah!
1 · Reply
jackedmund99
jackedmund99 Jul. 21 at 7:13 PM
$LCTX $GKOS fund managers, making a big deal out of this company 10 bill market cap sales estimated to be about 600 million says nobody’s paying attention to the eye marketplace. In phase 2 Well if they’re bringing attention, when are they gonna learn about $LCTX huge upside no one‘s paying attention. What a stral
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 20 at 5:35 PM
$GKOS careful. This may crash.
0 · Reply
IN0V8
IN0V8 Jul. 16 at 2:48 PM
$GKOS Opportunity Truist Securities raises target price to $180 from $160
0 · Reply
IN0V8
IN0V8 Jul. 8 at 2:59 PM
$GKOS Buy Citigroup raises target price to $175 from $162
0 · Reply
anachartanalyst
anachartanalyst Jun. 17 at 11:01 AM
$GKOS https://anachart.com/wp-content/uploads/2026/06/1781694067_soc-img.jpg
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jun. 8 at 1:41 PM
$GKOS let’s go!!!!!
0 · Reply
Roronao
Roronao Jun. 7 at 7:55 PM
$GKOS
0 · Reply
Niddi
Niddi Jun. 5 at 9:11 PM
$GKOS Current SP is the proof that it was heavily manipulated. How can these people manipulate the price so much easily? Corrupt market!
1 · Reply
Niddi
Niddi Jun. 4 at 2:03 PM
$GKOS Obvious manipulation to drag it down to under $100.
0 · Reply
Sarcozuchus26
Sarcozuchus26 Jun. 2 at 10:18 PM
$GKOS What a bargain guys, jump in!
0 · Reply